QPPV.COM KNOWLEDGE ASSESSMENT

Additional Pharmacovigilance Activities

Test your understanding of the concepts covered by Additional Pharmacovigilance Activities in the EU Risk Management Plan.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the most defensible way to justify an additional activity in RMP text?

Describe the study in technical detail without naming the safety concern Link the concern to the knowledge gap, explain why the design is appropriate, state the expected outcome and define timelines and closure criteria State only that the activity was requested internally Use identical wording for every product regardless of its population and risk profile

Question 2 of 10 Why should interim analyses and possible actions for urgent safety signals be specified in advance?

To permit unplanned endpoint changes whenever results are unexpected To establish a controlled process for reviewing emerging evidence, escalating signals and considering amendments or early termination To ensure that interim findings are never communicated to regulators To replace the final analysis with an interim analysis

Question 3 of 10 Which sequence best represents the logic that should be documented for an additional pharmacovigilance activity?

Study design → budget → safety concern → regulatory submission → outcome Safety concern → knowledge gap → additional activity → expected outcome → success or closure criteria Regulatory request → database selection → safety concern → protocol → marketing decision Routine surveillance → publication → study design → risk minimisation → knowledge gap

Question 4 of 10 What is the main purpose of predefined success or decision criteria in an additional activity?

To ensure that every study produces a statistically significant result To establish how possible findings will inform continuation, modification, closure or further risk management To avoid documenting inconclusive findings To allow the study team to change endpoints after seeing the results

Question 5 of 10 Which governance arrangement is particularly appropriate when an interventional study has important safety monitoring needs?

No independent review, because the sponsor already owns the data A DSMB or independent data monitor with an appropriate plan and stopping rules A publication committee with authority to suppress interim findings An informal group with no charter or documented membership

Question 6 of 10 Which action best supports data integrity in a non-interventional database study?

Allowing undocumented changes to the analytic dataset Maintaining traceability between source records and analytic datasets, with validation and query-resolution procedures Relying solely on the published abstract as the data record Removing all data queries before database lock without recording their resolution

Question 7 of 10 Which responsibility best reflects the QPPV's role in relation to additional pharmacovigilance activities?

Personally conducting all statistical analyses Providing strategic oversight, understanding high-level commitments and considering the safety impact of study outcomes Approving every patient consent form as the study investigator Replacing the sponsor's legal accountability for regulatory commitments

Question 8 of 10 A suspected adverse event may be a product-specific risk or a class-wide effect. Which approach most directly addresses this distinction?

A cohort study with an appropriate active comparator from the same therapeutic class A registry limited to patients who experienced the event A literature review without a prespecified comparator A PK study in healthy volunteers only

Question 9 of 10 Which documentation would most directly support an inspector's assessment of whether a regulatory commitment is being controlled?

A marketing forecast and sales incentive plan An obligation register showing origin, deliverables, timelines, responsible roles, status and mitigations for delays A list of published articles unrelated to the commitment A database user manual without milestone information

Question 10 of 10 Which statement best describes an appropriate closure decision for an additional activity?

Closure is appropriate whenever the study becomes inconvenient for the sponsor Closure should be supported by evidence that objectives were achieved or that the activity is no longer justified, with appropriate documentation and regulatory agreement where relevant Closure occurs automatically when the first interim analysis is completed Closure requires that the study demonstrate no safety signal

Additional Pharmacovigilance Activities

Cookie Settings